248 related articles for article (PubMed ID: 33011162)
21. In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells.
Louisa M; Soediro TM; Suyatna FD
Asian Pac J Cancer Prev; 2014; 15(4):1639-42. PubMed ID: 24641381
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
23. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
24. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
Strekalova E; Malin D; Rajanala H; Cryns VL
Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
[TBL] [Abstract][Full Text] [Related]
25. Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking.
Saeed M; Kadioglu O; Khalid H; Sugimoto Y; Efferth T
J Nutr Biochem; 2015 Jan; 26(1):44-56. PubMed ID: 25459885
[TBL] [Abstract][Full Text] [Related]
26. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
[TBL] [Abstract][Full Text] [Related]
27. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
28. Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.
van der Noord VE; van der Stel W; Louwerens G; Verhoeven D; Kuiken HJ; Lieftink C; Grandits M; Ecker GF; Beijersbergen RL; Bouwman P; Le Dévédec SE; van de Water B
Breast Cancer Res; 2023 May; 25(1):51. PubMed ID: 37147730
[TBL] [Abstract][Full Text] [Related]
29. Apigenin and its combination with Vorinostat induces apoptotic-mediated cell death in TNBC by modulating the epigenetic and apoptotic regulators and related miRNAs.
Nimal S; Kumbhar N; Saruchi ; Rathore S; Naik N; Paymal S; Gacche RN
Sci Rep; 2024 Apr; 14(1):9540. PubMed ID: 38664447
[TBL] [Abstract][Full Text] [Related]
30. ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.
Palasuberniam P; Yang X; Kraus D; Jones P; Myers KA; Chen B
Sci Rep; 2015 Aug; 5():13298. PubMed ID: 26282350
[TBL] [Abstract][Full Text] [Related]
31. Epigallocatechin-3-gallate promotes apoptosis and reversal of multidrug resistance in esophageal cancer cells.
Liu L; Ju Y; Wang J; Zhou R
Pathol Res Pract; 2017 Oct; 213(10):1242-1250. PubMed ID: 28964574
[TBL] [Abstract][Full Text] [Related]
32. Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo.
Lothstein L; Soberman J; Parke D; Gandhi J; Sweatman T; Seagroves T
Oncol Res; 2020 Dec; 28(5):451-465. PubMed ID: 32430093
[TBL] [Abstract][Full Text] [Related]
33. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells.
Gao Q; Li XX; Xu YM; Zhang JZ; Rong SD; Qin YQ; Fang J
Cancer Lett; 2020 Apr; 476():67-74. PubMed ID: 32061752
[TBL] [Abstract][Full Text] [Related]
34. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
35. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
36. The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Ata FK; Yalcin S
Anticancer Agents Med Chem; 2022; 22(2):371-377. PubMed ID: 34315389
[TBL] [Abstract][Full Text] [Related]
37. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer.
Merino VF; Cho S; Nguyen N; Sadik H; Narayan A; Talbot C; Cope L; Zhou XC; Zhang Z; Győrffy B; Sukumar S
Breast Cancer Res; 2018 Nov; 20(1):145. PubMed ID: 30486871
[TBL] [Abstract][Full Text] [Related]
38. Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression.
Guo L; Zheng P; Fan H; Wang H; Xu W; Zhou W
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28935760
[TBL] [Abstract][Full Text] [Related]
39. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
[TBL] [Abstract][Full Text] [Related]
40. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
